Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to…
--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan…